Hepalink Pharmaceutical Holdings Co., Ltd. (Hepalink Pharma-B) submitted the latest monthly securities report on May 31, 2024. The report shows that the company's statutory/registered capital stock remains at 20,000,000,000 shares, with a par value of US$0.000025 per share, for a total capital of US$500,000, and there were no changes this month. Due to the share option plan, the company issued 386,000 new shares this month, resulting in a decrease in the number of optioned shares under the share option plan from 39,250,950 to 38,864,950. The company received approval at the shareholder meeting on November 23, 2020, and confirmed that all relevant legal documents have been officially filed and all pre-listing conditions have been fulfilled. The report was submitted by the executive director, Wang Jinsong, on June 6, 2024.

Hepalink Pharmaceutical Holdings Co., Ltd. (Hepalink Pharma-B) submitted the latest monthly securities report on May 31, 2024. The report shows that the company's statutory/registered capital stock remains at 20,000,000,000 shares, with a par value of US$0.000025 per share, for a total capital of US$500,000, and there were no changes this month. Due to the share option plan, the company issued 386,000 new shares this month, resulting in a decrease in the number of optioned shares under the share option plan from 39,250,950 to 38,864,950. The company received approval at the shareholder meeting on November 23, 2020, and confirmed that all relevant legal documents have been officially filed and all pre-listing conditions have been fulfilled. The report was submitted by the executive director, Wang Jinsong, on June 6, 2024.